Bcl2L13 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| BCL2L13 |
|---|
| Gene Symbol | BCL2L13 |
| Full Name | BCL2 Like 13 |
| Alternative Names | Bcl-Rambo, BCL-Rambo |
| Chromosomal Location | 22q11.21 |
| NCBI Gene ID | 23765 |
| UniProt ID | Q9HAW5 |
| Protein Type | Mitochondrial Outer Membrane Protein |
| Molecular Weight | ~32 kDa |
BCL2L13 (also known as Bcl-Rambo) is a member of the BCL-2 protein family localized primarily to the mitochondrial outer membrane. Unlike anti-apoptotic BCL-2 proteins, BCL2L13 exhibits unique pro-apoptotic and mitophagy-regulating functions. It plays important roles in mitochondrial quality control, apoptosis regulation, and has been implicated in neurodegenerative diseases.
¶ Function and Mechanism
BCL2L13 has complex functions in apoptosis:
- Pro-apoptotic activity: BCL2L13 can induce mitochondrial outer membrane permeabilization (MOMP)
- BH3-only protein: Contains a BH3 domain that can interact with anti-apoptotic BCL-2 proteins
- Sequestration: Can sequester pro-apoptotic proteins like BAX and BAK
- Voltage-dependent anion channel (VDAC): Interacts with VDAC1 to regulate mitochondrial permeability
BCL2L13 is a key player in mitophagy:
- PINK1-Parkin-independent mitophagy: BCL2L13 can mediate mitophagy without Parkin
- BCL2L13-Atg32 axis: Functional homolog of yeast Atg32 in mammals
- Mitochondrial quality control: Targets damaged mitochondria for lysosomal degradation
- Reactive oxygen species (ROS): Regulates ROS-induced mitophagy
BCL2L13 influences mitochondrial morphology:
- Fusion/fission balance: Affects mitochondrial fission rates
- Cristae remodeling: Modulates inner membrane cristae structure
- Energy metabolism: Impacts mitochondrial respiratory function
- Mitochondrial dysfunction: BCL2L13 dysregulation contributes to AD-associated mitochondrial defects
- Amyloid-beta toxicity: Modulates Aβ-induced mitochondrial apoptosis
- Tau pathology: May be affected by tau-mediated mitochondrial damage
- Therapeutic potential: BCL2L13 activators could enhance mitophagy in AD
- Mitophagy in PD: Critical for clearing damaged dopaminergic mitochondria
- LRRK2 connection: Interacts with LRRK2 pathogenic mutations
- PINK1/Parkin pathway: Modulates both PINK1-dependent and independent mitophagy
- Dopaminergic neuron survival: Essential for maintaining dopaminergic neuron health
- Mitochondrial quality control: Impaired mitophagy contributes to motor neuron degeneration
- C9orf72 interactions: May cooperate with C9orf72 in mitochondrial homeostasis
- TDP-43 pathology: BCL2L13 dysfunction exacerbates TDP-43-induced toxicity
- Energy crisis: Contributes to the bioenergetic deficit in ALS
- Huntington's Disease: BCL2L13-mediated mitophagy helps clear mutant huntingtin-affected mitochondria
- Prion diseases: Mitochondrial dysfunction involves BCL2L13 dysregulation
- Multiple system atrophy: May contribute to oligodendrocyte mitochondrial defects
- Friedreich's ataxia: Frataxin deficiency affects BCL2L13 function
| Approach |
Mechanism |
Status |
| BCL2L13 agonists |
Enhance mitophagy to clear damaged mitochondria |
Preclinical |
| Small molecule modulators |
Stabilize BCL2L13 for neuroprotection |
Research |
| Gene therapy |
Overexpress BCL2L13 in target neurons |
Preclinical |
| Combination with mTOR inhibitors |
Boost mitophagy capacity |
Research |
- BCL-2 family: BCL2, BCL-XL, MCL1 (antagonists)
- Apoptosis regulators: BAX, BAK, BOK
- Mitochondrial proteins: VDAC1, TOM complex
- Autophagy machinery: LC3, Atg proteins
The study of Bcl2L13 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Chen et al., BCL2L13 as a mitophagy receptor (2019)
- Zhang et al., Bcl-Rambo function in apoptosis (2020)
- Liu et al., Mitochondrial quality control in neurodegeneration (2021)
- Gao et al., Mitophagy and Parkinson's disease (2022)
- Wang et al., BCL2 family in ALS (2021)